438 Studies Now Enrolling
A Phase 2, Randomized, Double-blind,Active-controlled, Dose-ranging, Parallel-designStudy of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
Study of New Drug (VX-548) in Patients with Painful Diabetic Peripheral Neuropathy
| Sponsor: | Vertex Pharmaceuticals |
| Enrolling: | Male and Female Patients |
| Study Length: | 5 Months |
| Clinic Visits: | 10 |
| IRB Number: | AAAT9369 |
| U.S. Govt. ID: | NCT05660538 |
| Contact: | Jorge Cabrera, CRC: 212-305-6035 / jec2273@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of VX-548 in participants with pain due to Diabetic Peripheral Neuropathy (DPN). To be in this study you must have DPN and be 18 through 80 years of age, inclusive, with presence of bilateral pain in lower extremities due to DPN for at least 1 year.
This study is closed
Do You Qualify?
| Are you a male and non-pregnant female patients between the ages of 18 and 80 years? | Yes | No |
| Have you been diagnosed with type 1 or type 2 diabetes? | Yes | No |
| Do you have a body mass index (BMI) of 18.0 to 40? | Yes | No |
| Do you have a history of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) within the last 2 years? | Yes | No |